11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2024

This “11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor: Understanding

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor: Overview

11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) is an intracellular enzyme that catalyses conversion of cortisone into cortisol; correspondingly, 11ß-HSD1 inhibitors inhibit this conversion. Researchers have emphasized the implication of 11-ß-hydroxysteroid dehydrogenase in the effector mechanism of aldosterone. This enzyme has two isoforms: (1) 11-hydroxysteroid dehydrogenase type 1 (11HSD1), which is present in the liver and fat and which activates cortisone to cortisol, regulating the physiological functions of these tissues, and (2) 11-hydroxysteroid dehydrogenase type 2 (11HSD2), which is present in the kidney and other classical target tissues for aldosterone (e.g., colon, salivary and sweat glands), where it inactivates cortisol to cortisone, thereby allowing aldosterone to bind to its renal receptors (when the enzyme is not active, e.g., when cortisol becomes a potent mineralocorticoid and produces a severe pseudohyperaldosteronism syndrome due to an inactivating mutation of the 11HSD2 gene). 11ß-HSD inhibitors may be a promising new class of candidate alcohol abuse medications, and existing 11ß-HSD inhibitor drugs may be potentially re-purposed for alcohol abuse treatment. There is a great significance of the 11ß-HSD1 inhibition in the treatment of several features of Metabolic disorders and provides the data about the development of 11ß-HSD1 inhibitors, as new agents for this purpose.

“11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor pipeline landscape is provided which includes the disease overview and 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor.

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor Emerging Drugs Chapters

This segment of the 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor Emerging Drugs

SPI 62: Sparrow PharmaceuticalsSPI-62 is a proprietary, oral small molecule, new chemical entity, HSD-1 inhibitor, designed to reduce intracellular cortisol levels and mitigate its numerous adverse effects. We are currently developing SPI-62 for conditions directly caused by an overproduction of cortisol in the body. SPI-62 may represent the first new mechanism of action in decades approved for patients suffering from endogenous Cushing’s syndrome (CS) and Autonomous Cortisol Secretion (ACS). In Phase 1 clinical trials, SPI-62 was generally well tolerated and demonstrated maximal liver HSD-1 inhibition and brain HSD-1 occupancy. In September 2022, the company announced that the first patient has been dosed in the RESCUE trial, a phase II clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor

There are approx. 5+ key companies which are developing the therapies for 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor. The companies which have their 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Sparrow Pharmaceuticals.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor drugs.

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor Report Insights

• 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor drugs?
• How many 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sparrow Pharmaceuticals
• Actinogen Medical
• PintoBio
• J2H Biotech

Key Products

• SPI-62
• Xanamem
• NTX-101
• SPI47
• J2H-1702

This product will be delivered within 1-3 business days.